SEEL Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	251 101
Gjennomsnittsvolum	441 245
Markedsverdi	5.64M
EPS	$0 ( 2024-03-05 )
Neste inntjeningsdato	( $-1.480 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0400
ATR14	$0.00300 (0.87%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-29	Golembiewski Michael Joseph	Buy	417	Common Stock
2024-01-12	Mehra Raj	Buy	70 383	Stock Option (right to buy)
2024-01-12	Golembiewski Michael Joseph	Buy	24 537	Stock Option (right to buy)
2024-01-04	Pascoe Richard W	Buy	1 666	Stock Option (right to buy)
2024-01-04	Dalesandro Margaret	Buy	1 666	Stock Option (right to buy)

INSIDER POWER
100.00
Last 92 transactions
Buy: 14 639 227 \| Sell: 4 987 490

Volum Korrelasjon

Lang: -0.12 (neutral)

Kort: -0.75 (moderate negative)

Signal:(51.762) Neutral

Seelos Therapeutics Inc Korrelasjon

10 Mest positive korrelasjoner
DCFC	0.951
WKHS	0.937
ADPT	0.934
NDLS	0.933
SLGG	0.927
WOOF	0.926
ORPH	0.919
RGF	0.919
TSLA	0.916
PRTS	0.916

10 Mest negative korrelasjoner
BCOR	-0.939
MCAA	-0.931
LCYAU	-0.926
KVSC	-0.926
EBACU	-0.922
BCSA	-0.919
GHRS	-0.917
IVCB	-0.916
HORI	-0.914
LPCN	-0.913

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Seelos Therapeutics Inc Korrelasjon - Valuta/Råvare

-0.12
( neutral )

-0.08
( neutral )

0.00
( neutral )

0.03
( neutral )

Seelos Therapeutics Inc Økonomi

Annual	2023
Omsetning:	$2.20M
Bruttogevinst:	$2.15M (97.41 %)
EPS:	$-7.73

FY	2023
Omsetning:	$2.20M
Bruttogevinst:	$2.15M (97.41 %)
EPS:	$-7.73

FY	2022
Omsetning:	$0
Bruttogevinst:	$-53 000.00 (0.00 %)
EPS:	$-21.48

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.730

Financial Reports:

No articles found.

Seelos Therapeutics Inc

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.